Reported Earlier, ESSA Pharma Terminates Phase 2 Study Evaluating Masofaniten Combined With Enzalutamide In Patients With mCRPC
Portfolio Pulse from Benzinga Newsdesk
ESSA Pharma has terminated its Phase 2 study of masofaniten combined with enzalutamide for mCRPC due to insufficient efficacy. The company will also halt other masofaniten studies and explore strategic options to maximize shareholder value.
November 01, 2024 | 6:48 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ESSA Pharma has terminated its Phase 2 study of masofaniten combined with enzalutamide for mCRPC due to insufficient efficacy. The company will also halt other masofaniten studies and explore strategic options to maximize shareholder value.
The termination of the Phase 2 study indicates that the drug combination did not meet efficacy expectations, which is a setback for ESSA Pharma's product pipeline. The decision to halt other studies and explore strategic options suggests potential restructuring or redirection of resources, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100